MDVN up +7.45% percent right now. $MDVN High is at 113.61

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2014 at 10:32 PM

MDVN up +7.45% percent right now. $MDVN High is at 113.61 and the Low 102.04 with current volume of 3,281,900.

Recent News posted below.

MDVN Medivation Inc Recent Headline News

Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 112.77 (+7.82)

Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 112.77 (+7.82)

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72)

Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 112.77 (+7.82), AOL: 42.68 (+0.45), AZN: 72.88 (+0.03)

Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 112.77 (+7.82)

Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 112.77 (+7.82)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 112.77 (+7.82)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), PRGO: 155.77 (+3.28), ALNY: 95.84 (+2.93)

Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ALNY: 95.84 (+2.93), HUM: 130.58 (-9.29)

Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), GERN: 2.33 (-0.07)

Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), GERN: 2.33 (-0.07), ILMN: 186.35 (-3.52)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), ALNY: 95.84 (+2.93), HSP: 56.32 (-0.32)

Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 112.77 (+7.82), AMSG: 51.50 (+0.16), DVA: 74.49 (-3.54), ALNY: 95.84 (+2.93)

Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)

Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), RNA: 12.14 (+0.08), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), ALDR: 16.57 (-0.25), ILMN: 186.35 (-3.52)

Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:44AM CST
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares surge nearly 22% on the day
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), ILMN: 186.35 (-3.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Shines in 2027 Latin America Rankings

Greenberg Traurig's Big Showing in Latin America It's not every day a law firm nails such a comprehensive accolade, but Greenberg Traurig has. The Legal 500 Latin America 2027 Edition has listed more than 60 of their talented attorneys and awarded them top-tier recognition in numerous practices. What's the deal here? It's all about their strategic foothold and unmatched...

Max Stock Gears Up for Q3 Earnings Report Nov. 17

Max Stock's Q3 Earnings Anticipation Ah, it’s that time again—when we wait with bated breath for another round of quarterly earnings. Max Stock Ltd. (TASE: MAXO) is prepping to spill the beans on their third quarter 2026 performance, with a conference call scheduled for November 17. Big day? You bet. Who's Leading the Call? The brains behind the operation, CFO Paz Oz...

ATI's Financial Runway: $1.42B Sales and Rising

ATI's Stellar Third Quarter: Beyond Expectations Today, ATI Inc. dropped a third-quarter performance that's got Wall Street abuzz—in a good way. The numbers speak volumes: ATI's sales soared by 26% to reach a cool $1.42 billion, smashing last year's results to bits. If you were banking on NYSE:ATI to keep your portfolio afloat, well, let's just say you're sitting...

BMO's Strategic Exit: Transportation Finance Sale

A Major Shift in BMO’s Strategic Direction When it comes to banking, BMO ain't playing small ball. They've just doubled down on their decision to part ways with their Transportation Finance and Vendor Finance operations, selling off a hefty part of these portfolios to Stonepeak. Now, that might sound like a mouthful, but hang tight, the nitty-gritty's where it gets...

McKay Brothers Enhances Fastest Routes for Market Data

Breaking Down McKay Brothers' Latest Maneuver Yeah, the financial market isn't just numbers and screens—it's about moving those numbers faster than a cheetah chasing prey. McKay Brothers knows this game inside and out, and they're laying down new wires, or rather, wireless, to make sure they've got the quickest routes in the room. Let me tell you, they're throwing money...

P.S. Active Teams with Barrett for Logistics Boost

Barrett Gets in the Game with P.S. Active Alright, picture this: an activewear brand hooked up with a logistics heavyweight. No, it's not just another round of corporate muscle-flexing—it's P.S. Active, spearheaded by Erika Hammond, partnering with Barrett Distribution Centers to elevate their fulfillment game from New Jersey's Somerset hub. The Stakes: More Than Just...

OPC Energy Refinances $825M for U.S. Power Plants

Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...

Tetragon's September Factsheet Offers Unique Insights

A Peek into Tetragon's Financial Playbook Every once in a while, you come across a player in the finance world that operates by its own rules. Tetragon Financial Group is one of those mavericks, and they've dropped their September 2026 Monthly Factsheet. Now here's a company that knows how to keep you guessing while serving up some real financial meat. Investment Strategy...

Nicely Network: A Game-Changer for B2B SaaS Marketing

Navigating the Reddit Marketing Labyrinth Life ain't a walk in the park for marketers these days, especially in the tech and SaaS arenas. Some folks seem to have cracked the code—or at least one part of it. Enter Nicely Network, which has just snagged the crown as the Best Reddit Marketing Agency for B2B SaaS & Software Companies, thanks to its knack for connecting...

LanguageLine AI App Earns Vizient Technology Kudos

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...